Business
Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the
About this update from Artelo Biosciences, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the appointment of seasoned industry executive John W. Beck to the Company’s Board of Directors. Mr. Beck brings more than 31 years of financial and strategic operational experience, including 15 years at publicly traded life science companies. Mr. Beck is succeeding Georgia Erbez on the Board of Directors and has been appointed as chair of the audit committee.\n “As a senior executive with significant pharmaceutical, financial and capital markets experience, John brings an impressive track record that we believe will benefit our Company as we enter our next stage of development and growth,” said Connie Matsui, Chair of the Board of Directors. “His qualifications include significant transactional experience, including leading the $1.2 billion sale of Ardea Biosciences to AstraZeneca, and raising over $400 million in public offerings. We are very pleased to welcome John to the Board of Directors. I would also like to thank Georgia Erbez for her contributions to the Company, as we advanced through key milestones.” “I am impressed by Artelo’s rapid progress from an initial concept to a Nasdaq-traded Company with a robust pipeline over the short span of two years,” said Mr. Beck. “With its innovative, high potential assets, I believe the Company is now in a position to deliver on significant clinical and development milestones. I look forward to assisting the team with strategic corporate and business development activities, as well as increasing visibility for Artelo within the investment community.” Mr. Beck currently serves as Senior Vice President, Finance and Chief Financial Officer of Ritter Pharmaceuticals, Inc. Mr. Beck’s experience includes 15 years as CFO of three publicly traded life sciences companies, including Ritter Pharmaceuticals, Ardea Biosciences, Inc., and Metabasis Therapeutics. Additionally, he served 5 years as Chief Executive Officer and co-owner of a private, medical product exporting business and 3 years as Chief Executive Officer of a development-stage, green, water treatment business. He holds a B.A. in Accounting from The University of Washington, Seattle and is a license...